/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR
DISSEMINATION IN THE UNITED STATES/
MONTREAL, Nov. 1, 2013 /CNW Telbec/ - OPMEDIC GROUP INC. ("OPMEDIC
Group") (TSX: OMG) announces that, at the special meeting of OPMEDIC
Group shareholders held earlier today in Montréal, shareholders
approved the previously announced proposed amalgamation (the
"Amalgamation") of OPMEDIC Group and Kemourmedic Acquisition Inc. (the
"Purchaser"), a wholly-owned subsidiary of Kemourmedic Group Inc. (the
"Purchaser Parent"), all of the outstanding shares of which are owned
by Drs. Pierre St-Michel, Marc Villeneuve and Jean-Yves Fontaine
(collectively, the "Founders"), pursuant to which OPMEDIC Group will be
99.48% of the votes cast were voted in favour of the Amalgamation,
including the requisite majority of the votes cast by shareholders
other than the Founders, the holding corporations of the Founders, the
Purchaser, the Purchaser Parent and their respective related parties.
Details of the voting results will be filed on the Internet at www.sedar.com under OPMEDIC Group's profile.
Assuming the satisfaction of all of the conditions to consummate the
Amalgamation, the Amalgamation is expected to become effective and to
close on or about November 4, 2013. Pursuant to the Amalgamation, each
shareholder other than the Founders will receive one redeemable share
of the amalgamated corporation for each Share held immediately prior to
the Amalgamation, and each redeemable share will be immediately
redeemed for $2.90 payable in cash as soon as practicable thereafter.
Applications will be filed to delist the common shares of OPMEDIC Group
from the Toronto Stock Exchange and to terminate OPMEDIC Group's status
as a reporting issuer under applicable Canadian provincial securities
About OPMEDIC Group
OPMEDIC Group is a company incorporated under the laws of the Province
of Quebec which provides healthcare-related services including surgical
and endoscopic facilities and services to patients and surgeons (with
its OPMEDIC division), fertility treatments, medical imaging,
laboratory services and diagnostic procedures (with its PROCREA Clinics
division, its subsidiary 8362556 Canada Inc. and a joint venture
7667264 Canada Inc.) and sperm banking services (with its PROCREA
Cryopreservation Centre subsidiary). The Shares trade on the TSX under
the symbol "OMG".
This press release may contain certain forward-looking statements.
Forward-looking statements are subject to certain risks and
uncertainties, many of which are beyond OPMEDIC Group's control. There
can be no assurance that such statements will prove to be accurate.
Consequently, actual results and future events may differ materially
from those anticipated by such statements. Readers should not rely
unduly on such forward-looking statements. The risks and uncertainties
include, but are not limited to, the satisfaction of the conditions to
consummate the Amalgamation including, the occurrence of any event,
change or other circumstances that could give rise to the termination
of the Amalgamation, a delay in the consummation of the Amalgamation or
failure to complete the Amalgamation for any other reason, the amount
of the costs, fees, expenses and charges related to the Amalgamation,
and the risks associated with general economic conditions. The
forward-looking statements in this press release are made as of the
date of this press release and, except as required by law, OPMEDIC
Group disclaims any obligation to update or revise publicly any
forward-looking statements, whether as a result of new information or
The content of this press release has not been approved by nor submitted
to the TSX which assumes no liability therefor.
SOURCE: OPMEDIC GROUP INC.
For further information:
Vice President Finance and Chief Financial Officer
(514) 345-8535, x 2260